Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +49.90%
#3 Velvet Velvet +37.98%
#4 DoubleZero DoubleZero +13.36%
#5 Akedo Akedo +13.09%
#6 Cross Cross +12.16%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.82%
#8 HOME HOME +11.04%
#9 Fake World Assets Fake World Assets +9.79%
#10 Momentum Momentum +9.40%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Kedudukan dalam Saham #40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Harga Saham
$0.02765
Disegerakkan terakhir: 2024-12-23
Modal Pasaran
$69.04K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Histogen Inc. (HSTO)

Kategori

Healthcare
Hasil untuk Histogen Inc. (HSTO)
Hasil pada Sep 2023 TTM: $19.00K
Menurut laporan kewangan terkini daripada Histogen Inc., hasil semasa syarikat (TTM) ialah $19.00K. Pada tahun 2021, syarikat memperoleh hasil sebanyak $919.00K penurunan berbanding hasil pada tahun 2020 iaitu $2.06M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Histogen Inc. dari 2011 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $19.00K -99.50%
2022 $3.77M 310.12%
2021 $919.00K -55.37%
2020 $2.06M -82.02%
2019 $11.45M -65.90%
2018 $33.59M -5.06%
2017 $35.38M 4,327.40%
2016 $799.05K 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 66,443,584.21%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 31,690,885.84%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 53,214,566.82%
BE